Demant

SEB lifts Demant target price, boosting buy outlook ahead of half‑year results, while Danish equities enjoy bank upgrades and a favorable macro backdrop.

Explore how Demant’s share dip and rising short‑selling reflect Denmark’s volatile hearing‑technology market amid geopolitical and economic shifts.

Explore why Danish equities, including Danske Bank & Demant, are muted amid global tech sell‑offs, geopolitics & tightening rates.

Nordic markets stay resilient as defensive and healthcare stocks outpace tech pullback, with Demant’s analyst upgrades boosting investor confidence.

Demant’s upgraded ratings and new hearing‑aid launch drive bullish outlook—Morgan Stanley, Danske Bank and DNB Carnegie see growth and a higher target price.

Bank of America upgrades Demant to buy, citing strong earnings, innovative hearing‑aid tech, global expansion and solid regulatory wins.

Demant’s Q1 2026 revenue beats expectations thanks to the premium Oticon Zeal, acquisitions, and cost‑saving plans—boosting margins and positioning the company for growth amid rising AI‑driven competition.

Demant sells Oticon Medical to Impilo, sharpening focus on core hearing‑aid tech, boosting margins and investor confidence while keeping implantable devices safe and available.

Demant A/S’s March 2026 AGM shows steady hearing‑care strategy, resilient margins, and tech‑driven growth amid Nordic market pullbacks.

Demant’s March 5 AGM shows no new moves, keeping its Danish C25 role steady—short‑sellers see limited upside, yet the company remains a stable investment choice.